Clinical Trial Update: A Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine [Phase 3]

View source ↗

Summary

Phase 3 trial comparing ipilimumab (3 mg/kg) to dacarbazine in chemotherapy-naïve stage IV melanoma in Chinese subjects; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Dacarbazine (dacarbazine)
• ipilimumab (ipilimumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Melanoma | Phase 3 | Status: COMPLETED | Results posted: 2020-05-19